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Enhanced transforming growth factor-b1 (TGF-b1) expression
in renal cells promotes fibrosis and hypertrophy during the
progression of diabetic nephropathy. The TGF-b1 promoter is
positively controlled by the E-box regulators, upstream
stimulatory factors (USFs), in response to diabetic (high
glucose) conditions; however, it is not clear whether TGF-b1
is autoregulated by itself. As changes in microRNAs (miRNAs)
have been implicated in kidney disease, we tested their
involvement in this process. TGF-b1 levels were found to be
upregulated by microRNA-192 (miR-192) or miR-200b/c in
mouse mesangial cells. Amounts of miR-200b/c were
increased in glomeruli from type 1 (streptozotocin) and type
2 (db/db) diabetic mice, and in mouse mesangial cells treated
with TGF-b1 in vitro. Levels of miR-200b/c were also
upregulated by miR-192 in the mesangial cells, suggesting
that miR-200b/c are downstream of miR-192. Activity of the
TGF-b1 promoter was upregulated by TGF-b1 or miR-192,
demonstrating that the miR-192-miR-200 cascade induces
TGF-b1 expression. TGF-b1 increased the occupancy of
activators USF1 and Tfe3, and decreased that of the repressor
Zeb1 on the TGF-b1 promoter E-box binding sites. Inhibitors
of miR-192 decreased the expression of miR-200b/c, Col1a2,
Col4a1, and TGF-b1 in mouse mesangial cells, and in mouse
kidney cortex. Thus, miRNA-regulated circuits may amplify
TGF-b1 signaling, accelerating chronic fibrotic diseases such
as diabetic nephropathy.
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Diabetes mellitus is associated with several debilitating
complications including kidney disease or diabetic nephro-
pathy (DN), a main cause for patients requiring painful and
costly dialysis. Accumulation of extracellular matrix proteins
such as collagen in the kidney mesangium and tubulointer-
stitium is one of the major hallmarks of DN and contributes
to renal failure.1,2 Transforming growth factor-b1 (TGF-b1)
levels and signaling are enhanced in renal cells during the
progression of DN. TGF-b1 plays a key role in mesangial cell
fibrosis under diabetic conditions by inducing the expression
of extracellular matrix proteins such as collagen.2–8 TGF-b1
is upregulated by high glucose (HG) in mesangial cells
(MCs) via the binding of upstream stimulatory factors
(USFs; positive regulators) at the glucose-response element
(CACGTG, also a typical E-box motif) in its promoter.9–11
On the other hand, TGF-b1 induces the expression of the
collagen type I a2 (Col1a2) gene by inhibiting the expression
of the E-box repressors, Zeb1/2, while increasing Tfe3
(transcription factor binding to IGHM enhancer 3), another
positive regulator of E-boxes.4,12 Under basal conditions,
Zeb1/2 repressors negatively regulate Col1a2 expression by
binding to E-box elements in the far upstream region of the
Col1a2 promoter.4,12 ZEB1/2 are now widely recognized as
general E-box repressors that bind to E-box elements in the
promoters of genes such as E-cadherin and collagens,
resulting in their repression.13–17
MicroRNAs (miRNAs) are short (B22 nucleotides) non-
coding RNAs that are important regulators of gene expres-
sion.18,19 miRNAs induce post-transcriptional gene repres-
sion by blocking protein translation via binding to the 30
untranslated region (UTR) of their target genes, or by inducing
mRNA degradation, and therefore have the potential to play
central roles in gene expression under physiological and
pathological conditions. Their widespread and distinct expres-
sion patterns under normal and disease states make miRNAs
attractive molecular therapeutic targets for human diseases,
especially because of the recent advances in the development of
chemically modified inhibitors of miRNAs like antagomirs20
and locked nucleic acid (LNA) antimiRs.21,22
miRNAs are also involved in progressive kidney diseases.23
miR-192 is upregulated by TGF-b1 in mouse MCs (MMCs)4
or ig ina l a r t i c l e http://www.kidney-international.org
& 2011 International Society of Nephrology
Received 29 October 2010; revised 29 December 2010; accepted 11
January 2011; published online 9 March 2011
Correspondence: Mitsuo Kato or Rama Natarajan, Department of Diabetes,
Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte,
California 91010, USA. E-mail: mkato@coh.org or RNatarajan@coh.org
358 Kidney International (2011) 80, 358–368
and by HG in human MCs,24 and in glomeruli of diabetic
mice, demonstrating that diabetic conditions induce miR-
192. Zeb2 is targeted and negatively regulated by miR-192 in
response to TGF-b1 in MMCs and this leads to increased
collagen expression due to relief of repression.4 TGF-b1 and
miR-192 levels are increased along with enhanced fibrosis in
the kidneys of diabetic FXR knockout mice.25 miR-192 is also
upregulated in the kidneys of other models of renal fibrosis
(unilateral ureteral obstruction in mice and a rat model of
remnant kidney disease) and in tubular epithelial cells treated
with TGF-b1 in a Smad3-dependent manner.26 On the other
hand, one study showed that TGF-b1 treatment decreased
miR-192 expression in a tubular epithelial cell line.27 Targeted
deletion of Dicer, a key enzyme involved in miRNA
biogenesis, from proximal tubules could protect against renal
ischemia–reperfusion injury.28 As miR-192 levels were
decreased in these tubular-specific Dicer knockout mice,
these data suggest that miR-192 inhibitors might be beneficial
in models of kidney injury and disease. miR-192 and miR-
200 family members regulate Zeb1/2 in epithelial-to-
mesenchymal transition (EMT) in cancer cells and other
established cell lines as Zeb1/2 are also repressors of
E-cadherin.27,29–35 miR-200 family members are also auto-
regulated by Zeb1/2 through E-boxes in their promoters.31,36
Although TGF-b1 expression is induced by HG in MCs via
the binding of USFs to E-boxes in the TGF-b1 promoter,9–11
it is not clear if the TGF-b1 promoter is autoregulated by
TGF-b1 itself or miRNAs. Here, we report that TGF-b1 is
upregulated by TGF-b1 through miR-192 and miR-200b/c
that target Zeb1/2. Furthermore, we observed that miR-200b/
c are also directly induced by miR-192, implicating miR-192
as a key upstream regulatory renal miRNA. These miRNA-
dependent positive feedback amplifying circuits may play
major roles in accelerating TGF-b1 expression and signaling
under diabetic conditions as proposed previously.22,37
RESULTS
Autoregulation of TGF-b1 is mediated by miR-192 in MMCs
TGF-b1 mRNA levels were significantly increased in MMCs
treated with TGF-b1 for 24 h in a dose-dependent manner
(5–10 ng/ml; Figure 1a). Time course showed no signifi-
cant increase of TGF-b1 mRNA levels at earlier time points
(1 or 6 h; Figure 1b). To test whether the TGF-b1 promoter is
also activated by TGF-b1, MMCs were transfected with
pA835luc (luciferase reporter plasmid driven by the mouse
TGF-b1 promoter containing glucose response element,
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Figure 1 |Auto-upregulation of transforming growth factor-b1
(TGF-b1) in mouse mesangial cells (MMCs). (a) Dose-response
curve of TGF-b1 mRNA levels (assessed by quantitative real-time
PCR) in MMCs treated with exogenous recombinant TGF-b1 for
24 h (mean and s.e., n¼ 4). Significant increase was detected at
5–10 ng/ml of TGF-b1. (b) Time course study of TGF-b1 mRNA
levels in MMCs treated with 10 ng/ml of TGF-b1 (mean and s.e.,
n¼ 4). Significant increase was detected only at 24 h. (c) Mouse
TGF-b1 promoter (including upstream glucose response element,
CACGTG, also known as E-box) Luc reporter (pA835luc) activity
was significantly increased by TGF-b1(10 ng/ml for 24 h) (mean
and s.e., n¼ 4). SD, serum depletion. (d) miR-192 mimic
oligonucleotides (oligos) increased TGF-b1 promoter Luc reporter
(pA835luc) activity, whereas miR-192 inhibitor oligos inhibited the
TGF-b1-induced reporter activity (mean and s.e., n¼ 4). NC,
negative control oligo. ***Po0.001, **Po0.01, and *Po0.05,
respectively.
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CACGTG, also known as E-box).9,38 A significant increase
(approximately twofold) in luciferase activity was observed in
MMCs treated with TGF-b1 (Figure 1c). These results
demonstrate that TGF-b1 induces its own expression and
promoter activity (autoregulation) in MMCs.
Next, we tested whether miR-192 can regulate the TGF-b1
promoter, because miR-192 increases gene expression
through E-box enhancer elements by downregulating the E-
box repressors Zeb1/2,4,22 and the TGF-b1 promoter is also
regulated by an E-box in its promoter.9–11 Transfection of
MMCs with miR-192 mimic significantly increased reporter
activity of pA835luc in MMCs compared with negative
control (NC; Figure 1d). Conversely, miR-192 inhibitor
significantly decreased reporter activity under basal as well as
TGF-b1-treated conditions. These results suggest that
inhibition of Zeb1/2 by miR-192 may enhance TGF-b1
promoter activity in response to TGF-b1.
miR-200b and miR-200c are increased in MMCs treated with
TGF-b1 and in glomeruli of diabetic mice
As miR-200 family members target both Zeb1 and Zeb2,29–34
and are also self-regulated by Zeb1/2 through E-boxes in their
promoters,31,36 miR-200 family members may mediate TGF-
b1 signaling in MCs. The miR-200 family consists of two
groups based on their seed sequences: group 1 (miR-141 and
miR-200a) and group 2 (miR-200b, miR-200c, and miR-429;
Figure 2a). miR-200b and miR-200c levels as well as miR-192
were significantly increased by TGF-b1 (Figure 2b). miR-
200b and miR-200c levels were also increased in the
glomeruli of both type 1 (streptozotocin-injected C57BL/6
mice) and type 2 diabetic mice (db/db mice) compared with
their respective controls (Figure 2c). Increased levels of miR-
192 and miR-200b were also observed in the glomeruli of
streptozotocin-injected mice on the DBA/2J background
(Supplementary Figure S1 online). These results suggest that
miR-200b and miR-200c may also play a role in MC
dysfunction associated with DN.
miR-200b and miR-200c are upregulated by miR-192 in MMCs
Because miR-200 family members can be self-regulated by
Zeb1/2,31,36 we tested whether miR-192 upregulates miR-
200b/c by targeting Zeb1/2 at E-boxes in miR-200b/c
promoters. miR-192 mimic significantly increased the miR-
200b (B2.5-fold) and miR-200c (B1.5-fold) levels com-
pared with control (NC) (Figure 3a and b). TGF-b1 again
significantly increased the miR-200b (approximately three-
fold) and miR-200c (1.6-fold), and this was reversed by the
miR-192 inhibitor (Figure 3a and b). These results indicate
that TGF-b1-induced miR-200b/c upregulation is mediated
by miR-192 in MCs.
TGF-b1 is upregulated by miR-192 and miR-200b in MMCs
As TGF-b1 is upregulated by HG in MCs through the actions
of USFs at the E-box in its promoter,9–11 we tested if miR-192
or miR-200b affects TGF-b1 mRNA expression. miR-192 or
miR-200b mimic significantly increased TGF-b1 mRNA
levels, whereas their inhibitors reversed the stimulatory effect
of TGF-b1 (Figure 3c). Because miR-200b is upregulated by
miR-192 (Figure 3a), these results suggest that the observed
autoregulation of TGF-b1 is mediated by a miRNA cascade
from miR-192 to miR-200b.
miR-200b/c suppresses Zeb1 through its 30UTR
Treatment of MMCs with miR-200b or miR-200c signifi-
cantly decreased Zeb1 protein levels relative to NC (Figure 4a
and b). This was similar to the inhibitory effect of TGF-b1 on
Zeb1 (Figure 4c and d). Conversely, inhibitors of miR-200b
reversed the inhibitory effect of TGF-b1 on Zeb1 protein
expression (Figure 4e and f). These results further support
the role of TGF-b-induced miR-200b in Zeb1 repression.
Next, we tested if mouse Zeb1 is a direct target of miR-
200b and miR-200c also in MMCs. Luciferase (Luc) reporters
were constructed containing the 30UTR sequence of the
mouse Zeb1 gene with two potential target sites (and
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Figure 2 | The expression of miR-200 family members in
mouse mesangial cells (MMCs) treated with transforming
growth factor-b1 (TGF-b1) and in the glomeruli of diabetic
mice. (a) Mature sequences of miR-200 family members. miR-200
family members are divided into two groups, group 1 (miR-141
and miR-200a) and group 2 (miR-200b, miR-200c, and miR-429),
based on their seed sequences underlined. (b) Expression levels of
miR-200 family member and miR-192 and miR-215 in MMCs
treated with or without TGF-b1 (10 ng/ml for 24 h). miR-200b and
miR-200c levels were significantly increased by TGF-b1, with no
significant change in miR-141 or miR-429 (mean and s.e., n¼ 3).
miR-192 levels were increased and miR-215 levels decreased, as
reported previously.4 (c) miR-200b and miR-200c levels were
increased in diabetic mice glomeruli relative to respective control
non-diabetic mice (mean and s.e., n¼ 4). CTR, control; STZ,
streptozotocin. ***Po0.001, **Po0.01, and *Po0.05, respectively.
360 Kidney International (2011) 80, 358–368
or ig ina l a r t i c l e M Kato et al.: Autoregulation of TGF-b1 by a miRNA circuit
mutations in these sites) for miR-200b/c identified by
TargetScan39 (Figure 5a). miR-200b or miR-200c significantly
inhibited the Zeb1 30UTR Luc reporter activity, whereas the
NC had no effect (Figure 5b). These results are consistent
with our findings that miR-200b or miR-200c inhibited Zeb1
protein levels in MMCs (Figure 4a). Given that miR-200b
and miR-200c belong to the same group and share the same
miR-200c levels
**
*
**
SD
TGF-β1
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0
NC NC
N
om
al
iz
ed
 m
iR
-2
00
c 
le
ve
ls
miR-192
mimic
miR-192
inhibitor
TGF-β1 mRNA
*
***
**
SD
TGF-β1
0.5
1
1.5
2
2.5
N
or
m
al
iz
ed
 le
ve
ls
*
***
0
NC miR-
200b
miR-
200b
NC
Mimic
miR-
192
miR-
192
Inhibitor
***
miR-200b levels SD
TGF-β1
1
1.5
2
2.5
3
3.5
***
***
0
0.5
NC NC
N
or
m
al
iz
ed
 m
iR
-2
00
b 
le
ve
ls
miR-192
mimic
miR-192
inhibitor
Figure 3 |miR-200 family members and transforming growth
factor-b1 (TGF-b1) are upregulated by miR-192 in mouse
mesangial cells (MMCs). (a, b) miR-192 mimic or inhibitor
oligonucleotides (oligos) were transfected into MMCs and miR-
200b/c levels examined by real-time quantitative PCR (qPCR).
Effects of miR-192 mimic and inhibitor on the expression of (a)
miR-200b and (b) miR-200c. SD, serum depletion. miR-192
significantly increased miR-200b and miR-200c levels in MMCs
compared with negative control (NC). miR-192 inhibitor
ameliorated the TGF-b1(10 ng/ml for 24 h)-induced increases in
miR-200b and miR-200c levels (mean and s.e., n¼ 3). (c) Effects of
miR-192 and miR-200b mimics and inhibitors on the expression of
TGF-b1. miR-192 or miR-200b significantly increased TGF-b1 levels
in MMCs. Conversely, miR-192 or miR-200b inhibitor significantly
attenuated the TGF-b1-induced increase in TGF-b1 levels (mean
and s.e., n¼ 3). ***Po0.001, **Po0.01, and *Po0.05, respectively.
NC
miR-200 Mimic SD TGF-β1
-Zeb1
-Zeb1
-β-Actin
***
**
Zeb1
**
-β-Actin
Zeb1/actin
1
1.2 *
0
0.2
0.4
0.6
0.8
1
1.2
N
or
m
al
iz
ed
 le
ve
ls
0
0.2
0.4
0.6
0.8
SD
N
or
m
al
iz
ed
 le
ve
ls
NC 200a 200b 200c
Mimics
TGF-β1
MMC
a b c
-Zeb1
-β-Actin
0 20 50 nmol/l
miR-200b inhibitors
10 ng/ml TGF-β1
*
*Zeb1
3.5
4
4.5
0
0.5
1
1.5
2
2.5
3
NC
N
or
m
al
iz
ed
 le
ve
ls
miR-200b inhibitor
20
nmol/l
50
nmol/l
Figure 4 |Zeb1 is inhibited by miR-200b and miR-200c.
(a) Zeb1 protein levels are significantly decreased by miR-200b
or miR-200c (or miR-200a) in mouse mesangial cells (MMCs).
NC, negative control of mimic oligonucleotide (oligo).
(b) Quantification of Zeb1 protein levels (mean and s.e., n¼ 3).
(c) Decreased levels of Zeb1 in transforming growth factor-b1
(TGF-b1) (10 ng/ml for 24 h)-treated MMCs. SD, serum depletion.
(d) Quantification of Zeb1 protein levels (mean and s.e., n¼ 3).
(e) Increase of Zeb1 protein levels by miR-200b inhibitor.
All samples were treated with TGF-b1 (10 ng/ml for 24 h).
(f) Quantification of Zeb1 protein levels (mean and s.e., n¼ 3).
***Po0.001, **Po0.01, and *Po0.05, respectively.
Kidney International (2011) 80, 358–368 361
M Kato et al.: Autoregulation of TGF-b1 by a miRNA circuit o r ig ina l a r t i c l e
seed sequence, they likely share the same targets (Figure 2a).
Single mutations in the Zeb1 30UTR (M1 or M2) resulted in
an attenuated response to miR-200b compared with the wild-
type construct (Figure 5c). A construct containing both
mutations M1 and M2 completely lost the response to miR-
200b (Figure 5c), confirming that these two sites in the Zeb1
30UTR are bona fide targets of miR-200b.
miR-192 and miR-200b upregulate Col1a2 via E-box enhancer
region
Collagens are regulated through E-box sites in the upstream
regions.4,12,16,17 As our current results showed that miR-200b
and miR-200c inhibit Zeb1 expression in MMCs through the
Zeb1 30UTR (Figures 4 and 5), we examined the effects of
miR-200b on Col1a2 gene expression and whether it
cooperates with miR-192. A significant increase in Col1a2
expression was detected in MMCs transfected with a
combination of miR-192 and miR-200b, whereas a slight
but not significant increase was noted with either miR-192 or
miR-200b alone (Figure 6a). In addition, we also observed a
cooperation between miR-192 and miR-200b in increasing
the activity of a Luc reporter containing the E-box-Col1a2
promoter12 (Figure 6b). As shown previously, the inhibition
of both Zeb1 and Zeb2 is necessary for significant induction
of Col1a2.4 Therefore, the simultaneous transfection of miR-
200b (to inhibit Zeb1) and miR-192 (to inhibit Zeb2) may be
necessary for significant induction of Col1a2. On the other
hand, miR-200b inhibitor alone was sufficient to significantly
repress Col1a2 expression (Figure 6c). Consistent with the
above observations, inhibitors of miR-192 and miR-200b
each attenuated TGF-b1-induced E-box-Col1a2 promoter
Luc activity (Figure 6d). Together, these results indicate that
miR-200b/c upregulate Col1a2 gene via inhibition of Zeb1 in
collaboration with miR-192 (inhibitor of Zeb2).
TGF-b1, miR-192, or miR-200b upregulate Col4a1
As an increase of type IV collagens occurs in early stages of
DN,7,8 we also tested the expression of Col4a1 gene. Col4a1
mRNA levels were significantly increased by miR-192 or miR-
200b as well as TGF-b1 in MMCs (Figure 6e). Inhibitors of
miR-192 or miR-200b significantly attenuated TGF-b1-
induced Col4a1 mRNA expression. Interestingly, we identi-
fied at least 12 potential E-boxes in the promoter region of
Col4a1 gene (Supplementary Figure S2 online). Thus, Col4a1
gene may be regulated by TGF-b1 through these E-boxes via
miR-192 and miR-200b in MMCs.
TGF-b1 increases USF1 and Tfe3 occupancies, but decreases
Zeb1 occupancy on the TGF-b1 promoter E-box
Next, we used chromatin immunoprecipitation (ChIP) assays
to examine the occupancy of E-box regulators, USF1 and
Tfe3 (positive) and Zeb1 (negative), on the TGF-b1 promoter
in MMCs treated with TGF-b1 or HG (25mmol/l).
Occupancy was determined by amplification of TGF-b1
promoter E-box region (Figure 7a) using quantitative real-
time PCR of ChIP-enriched DNA. USF1 occupancy was
significantly increased by HG treatment compared with
normal glucose (5.5mmol/l) or Mannitol (19.5mmol/l)
(Figure 7b), as reported.9 Interestingly, TGF-b1 treatment
showed significant enrichment of USF1 as well as Tfe3, with
reciprocal significant depletion of Zeb1 compared with
untreated control (serum depletion; Figure 7c). We also
examined occupancies of these E-box regulators on the
Col1a2 enhancer E-box region and observed that TGF-b1
increased Tfe3 and decreased Zeb1 enrichments at this
Col1a2 enhancer as also noted in our previous studies.4,12
However, no significant change of USF1 occupancy on
Col1a2 E-box region was detected (Figure 7d and e). These
results suggest that the downregulation of Zeb1 by miR-200b/
c induced by TGF-b1 can enhance both TGF-b1 and Col1a2.
But the recruitment of USF1 to TGF-b1 promoter E-box
region may be different from Col1a2 enhancer E-boxes.
miR-192 inhibitor decreases the expression of miR-200 family
members as well as Col1a2, Col4a1, and TGF-b1 in MMCs
in vitro and in mouse kidney cortex in vivo
miR-192 is a key candidate upstream regulator that controls
the expression of downstream genes such as the miR-200
family, Col1a2, Col4a1, and TGF-b1 through E-boxes in
their promoters. Thus, we tested whether the inhibition of
miR-192 could have protective effects. miR-192 inhibitor
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significantly inhibited the expression of miR-141, miR-200b,
miR-200c, Col1a2, Col4a1, and TGF-b1, as well as miR-192
in vitro in cultured MMCs (Figure 8a).
To evaluate the in vivo relevance, we tested the effects of
miR-192 inhibition in mice using LNA-modified antisense
miR-192 (LNA-antimiR-192).22 Injection with LNA-antimiR-
192 decreased the expression of miR-192, miR-141, miR-
200b, miR-200c, Col1a2, Col4a1, and TGF-b1 in the mouse
renal cortical tissues in vivo (Figure 8b).
DISCUSSION
In this study, we observed for the first time that TGF-b1 can
be auto-upregulated in MMCs by the activation of a miRNA
cascade including miR-192 and key miR-200 family mem-
bers. It is likely that, initially, diabetic conditions (HG)
induce TGF-b1 through various mechanisms including
binding of USFs (E-box activators) to its promoter.9–11 Next,
miR-192 can be upregulated by TGF-b1 possibly via Smad3
and p53 in MMCs and diabetic kidneys as the miR-192
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promoter has Smad and p53 binding sequences and is
upregulated by Smad3 or p53.26,40 Then, miR-192 can target
and downregulate Zeb1/2 (E-box repressors)4,27,35,41 and
thereby enhance the expression of TGF-b1 through the
recruitment of USF1 and Tfe3 but dissociation of Zeb1 from
the E-box region in the TGF-b1 promoter to create an
amplifying circuit (Figure 9). Interestingly, we found that key
miR-200 family members were also upregulated by TGF-b1
in MMCs and in the glomeruli of diabetic mice. In addition,
miR-192 also increased miR-200b/c (Figure 3) probably
through E-boxes in their promoters.31,36 miR-200 family
targets Zeb1/2 and also enhances the expression of miR-200
family itself though E-boxes and this results in another
positive feedback circuit to accelerate the downstream
signaling (Figure 9). We identified at least two miR-200b
target sites in the mouse Zeb1 30UTR and confirmed that
miR-200b targets Zeb1 in MMCs (Figure 5). These results in
MMCs are consistent with other reports showing that miR-
200 family members suppress Zeb1 expression by targeting its
30UTR,29–33 and suggest that Zeb1/2 inhibition is a major
function of the miR-200 family. Further decrease of Zeb1/2
by miR-200 family in MMCs can augment the expression of
TGF-b1. These signaling loops may be a key feature of
chronic diseases like DN.12,22,37
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miR-200b also increased Col1a2 expression and promoter
activity by collaborating with miR-192 (Figure 6). Simulta-
neous transfection of miR-192 (inhibitor of Zeb2) and miR-
200b (inhibitor of Zeb1) was necessary for significant
induction of Col1a2 or its promoter activity (Figure 6).
These results are consistent with previous data showing that
Zeb2 inhibition by miR-192 alone was not sufficient but also
needed Zeb1 inhibition (by short hairpin RNAs) to elicit a
significant increase in Col1a2 expression in MCs.4 On the
other hand, single transfection of an inhibitor of either miR-
192 or miR-200b was sufficient to inhibit Col1a2 expression
and its promoter activity (Figure 6). Thus, inhibition of both
Zeb1 and Zeb2 is necessary for significant induction of
Col1a2, whereas the presence of just one of these repressors
(Zeb1 or Zeb2) is sufficient to suppress Col1a2. However,
unlike Col1a2, miR-200b/c, Col4a1, and TGF-b1 were
upregulated by either miR-192 or miR-200b alone (Figures
3 and 6). As Col1a2 upstream E-box region is regulated by
multiple factors like Tfe3, Tsc-22, and Ybx112 besides Zeb1/2,
induction of Col1a2 might involve additional or more
complex mechanisms compared with TGF-b1 Col4a1 or
miR-200 family promoters.
ChIP experiments showed significant decrease of Zeb1
occupancy on E-box regions of TGF-b1 promoter and Col1a2
enhancer in MMCs treated with TGF-b1 (Figure 7). These
results further support the notion that suppression of E-box
repressor Zeb1 by miR-200b/c induced by TGF-b enhances
the expression of TGF-b1 and Col1a2. Although E-box
activator Tfe3 occupancy was increased by TGF-b1 at E-box
regions of both TGF-b1 and Col1a2 genes, USF1 occupancy was
increased only at E-box region of TGF-b1 gene. These results
demonstrate similarities in the regulation of these two genes
with respect to decrease in Zeb1, but differences in the
recruitment of positive factors. As we noted at least 12 potential
E-boxes in the Col4a1 gene promoter, Col4a1 may be regulated
by TGF-b1, miR-192, or miR-200b through these E-boxes
similar to the regulation of TGF-b1, miR-200b, and Col1a2,
although more studies are required to clarify this.
miR-200 family members also regulate Zeb1 and Zeb2 in
EMT in cancer29–34 and were decreased during EMT of the
canine kidney cell line (MDCK) treated with TGF-b1 for long
time periods (2–3 weeks).29 As type I collagen induces
EMT,42,43 it is possible that there is a biphasic regulation in
which miR-192 and 200 family are upregulated by TGF-b1 at
early time points (6–24 h) that decreases Zeb1 and Zeb2 to
induce type I collagen in MMCs. This increase in collagen
may subsequently induce EMT (maybe by decreasing these
miRNAs) at later time points. In the NRK52E epithelial cell
line, Chung et al.26 reported that miR-192 levels were
increased by 2 ng/ml TGF-b1 at 1–24 h, whereas Wang
et al.35 reported that miR-192 levels were decreased by
10 ng/ml TGF-b1 at 3 days with no data at earlier time
points. Although the dose of TGF-b1 might dictate its
response, it is possible that initially TGF-b1 increases miR-
192 and miR-200 family to promote type I collagen
expression (up to 24 h), whereas miR-192 levels may be
reduced at later time periods (3 days to weeks). Furthermore,
there is no EMT in mesangial cells, and hence, it is highly
likely that the response of miRNAs to TGF-bmay be cell-type
specific and context dependent. On the other hand, fibrosis
and accumulation of extracellular matrix proteins in MCs
and tubular cells are well-established features of DN in both
human and mice.1,2 Thus, the upregulation of collagen
expression by TGF-b1 via increases in miR-192 and miR-
200b and concomitant decrease in Zeb1/2 in MCs may be a
key feature of DN and possibly more relevant during the early
stages of diabetic kidney injury. Interestingly, increased levels
of miR-192 and miR-200 family were observed in human
kidneys from patients with hypertensive nephrosclerosis, IgA
nephropathy, and lupus nephritis,44–46 and in some animal
models of kidney injury,25,26,28 further supporting the
miRNA-mediated mechanism of TGF-b1 auto-upregulation
and enhanced renal fibrosis. On the other hand, it was also
reported that miR-192 expression decreased with increased
severity of DN and fibrosis; however, normal levels of miR-
192 in healthy kidneys were not provided for comparison.27
Clearly, more work is needed to further evaluate these aspects
in renal cells.
Notably, miR-192 is regulated by Smad3 and p53.26,40
Numerous mutations in p53 and Smad genes have been
found in cancer cells and immortalized cell lines47–49 that
may affect the miR-192 response to TGF-b1 in these cells. In
other words, p53 and Smad genes may also be decision
makers of TGF-b1 response. In fact, mutant p53 changes the
response to TGF-b1 via Smad interaction.50 Kidney injury
TGF-1
Diabetic condition in glomerular mesangial cells
Positive feedback
Accelerating signaling
miR-192
miR-200b/cTfe3 and/or USF1
Upstream E-boxes
Zeb1/2
miR-200 family
TGF-1 TGF-1Upstream E-box
Col1a2
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Figure 9 |Auto-upregulation of transforming growth factor-b1
(TGF-b1) mediated by a microRNA (miRNA) cascade in mouse
mesangial cells (MMCs). Diabetic conditions increase the
expression of TGF-b1 that induces miR-192 (inhibitor of Zeb1/2)
probably via mechanisms involving the actions of Smad3 and p53.
miR-200b/c are also upregulated because of the downregulation
of Zeb1/2 by miR-192. Because miR-200b/c target Zeb1/2, this can
lead to a further decrease of Zeb1/2 and further augment the
expression of miR-200b/c, TGF-b1, collagen type I a2 (Col1a2), and
Col4a1 through loss of repression, along with gain of activation
(via Tfe3 and/or upstream stimulatory factor 1 (USF1)) at their
E-boxes. These signaling loops accelerate TGF-b1 signaling and
downstream gene expression involved in the progression of
chronic kidney diseases like diabetic nephropathy (DN).
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and fibrosis were inhibited in p53 or Smad3 knockout
mice.26,51 In this study, we used primary mouse MCs and
glomeruli that have normal intact p53 and Smad genes.
Therefore, the response of miR-192 and miR-200 family to
TGF-b1 in primary MMCs may be different from those
reported in cancer or immortalized kidney cell lines, and might
explain some of the discrepancies in TGF-b1 responses. They
also indicate the importance of using primary cells (at early
passage) for studying models of renal fibrosis or injury and
especially the mediatory role of miRNAs.
miR-200 family was also reported to control phosphati-
dylinositol-3-kinase signaling by targeting Fog2, an inhibitor
of phosphatidylinositol-3-kinase.52 As phosphatidylinositol-
3-kinase/Akt activation in diabetic kidney cells induces
hypertrophy and fibrosis,12,22,53,54 upregulation of miR-200
family members may also activate Akt through inhibition of
Fog2 to promote mesangial hypertrophy. As miR-192 also
activates Akt kinase and fibrosis by inducing miR-216a and
miR-217 that target Pten,22 this cascade of miRNAs (miR-200
family, miR-216a, and miR-217) initiated by miR-192 may
enhance Akt activation, hypertrophy, and fibrosis in MCs.
In summary, these novel miR-mediated circuits demon-
strated in this study can lead to the auto-upregulation of
TGF-b1 and amplification of TGF-b1 signaling, and thereby
accelerate chronic fibrotic kidney diseases including DN
(Figure 9). The ability of the miR-192 inhibitor to repress the
expression of miR-200 family members, TGF-b1, Col4a1, and
Col1a2, both in vitro (MMCs treated with TGF-b1) and in
vivo (mouse kidney cortex), suggests that miR-192 could be a
novel target for the prevention or treatment of fibrotic
disorders like DN as well as other diseases where TGF-b
signaling is hyperactive.
MATERIALS AND METHODS
Mice
All animal studies were conducted according to a protocol approved
by the institutional animal care and use committee. Induction of
diabetes by streptozotocin injections in C57BL/6 mice was carried
out as described.4 Mice were used 7–8 weeks after the onset of
diabetes. Type 2 diabetes db/db mice and genetic control db/þ mice
(10–12 weeks old) were obtained from Jackson Laboratories (Bar
Harbor, ME). Glomeruli were sieved from renal cortical tissue as
described.4,53
Cell culture
Primary MMCs were isolated and cultured as described.4 Recombi-
nant human TGFb1 was from R&D Systems (Minneapolis, MN).
Real-time quantitative PCR
Real-time quantitative PCR was performed using SYBR Green PCR
Master Mix and 7300 Real-Time PCR System (Applied Biosystems,
Foster City, CA), as reported.4,12,22 PCR primer sequences were:
mouse TGF-b1, 50-GGACTCTCCACCTGCAAGAC-30 and 50-GACT
GGCGAGCCTTAGTTTG-30; mouse Col4a1, 50-GCCTTCCGGGCT
CCTCAG-30 and 50-TTATCACCAGTGGGTCCG-30. miRNA expres-
sion levels were also confirmed by miScript System (Qiagen,
Valencia, CA).
Western blot analyses
These were performed as described.4 Antibodies against ZEB1
(Santa Cruz Biotechnology, Santa Cruz, CA) and b-actin (Cell
Signaling, Beverly, MA) were used in a 1:1000 dilution.
Plasmids and 30UTR reporters
pA835luc was a generous gift from Dr Kumar Sharma (University of
California, San Diego).9,38 Mouse Col1a2 promoter luciferase plasmid
(E-box-Col1a2P-luc) was described previously.12 30UTR of mouse
Zeb1 was amplified using primers Zeb1-30UTR-F, 50-CCAACTCGAGT
TCTTCTAAAAGGAAATTCTACTTGG-30 and Zeb1-30UTR-R, 50-GA
GAGCGGCCGCGGGAATTCTGTAGTGCAGAAGTTCTC-30.
The PCR fragment was digested with XhoI and NotI and cloned
into psiCheck2 (Promega, Sun Luis Obispo, CA). Potential
miR200b/c site mutants were made by site-directed mutagenesis as
described22 using primers for Site1, 50-GCATGGCTAGCAGCTGTAT
CACTCTTA-30 and 50-TAAGAGTGATACAGCTGCTAGCCATGC-30
and for Site2, 50-AAATCCGCTTCAGCTGTTTATTATGTT-30 and
50-AACATAATAAACAGCTGAAGCGGATTT-30. Bases substituted
are underlined.
Luciferase assays
MMCs were transfected with plasmids and/or miRNA mimics or
inhibitors using Nucleofector (Lonza, Walkersville, MD). Basic
Nucleofector Kit (Lonza) was used. After 48 h, luciferase activities
were measured as described.4,22
miRNA oligonucleotides
Oligonucleotides representing the miRNA mimics, the NC mimics,
miRNA inhibitors, and NC inhibitors were obtained from
Dharmacon (Lafayette, CO). LNA-modified anti-miR-192 was from
Exiqon (Vedbaek, Denmark).22
ChIP assays
ChIP assays were performed as reported.4,9,12,22 Briefly, MMCs were
treated with 10 ng/ml TGF-b1 or HG (25mmol/l) condition for 24 h
and then formaldehyde fixed. The crosslinked chromatin was
sheared and immunoprecipitated using antibodies against USF1
(Santa Cruz Biotechnology), Tfe3 (BD Bioscience, San Diego, CA),
or Zeb1. ChIP-enriched DNA was purified and used as template for
real time quantitativeqPCRs using primers spanning Col1a2 or TGF-
b1 E-box regions as described.4,9
LNA-antimiR injections in mice
LNA anti-miR-192 was subcutaneously injected (2.5mg/kg) into
C57BL/6 mice and renal cortical tissues harvested 6 h later as
previously described.22
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